Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Halozyme Therapeutics, Inc. (HALO) vs Summit Therapeutics PLC (SMMT)

Halozyme Therapeutics, Inc. and Summit Therapeutics PLC are both Biotechnology companies. Halozyme Therapeutics, Inc. and Summit Therapeutics PLC are of similar size ($13.1B and $13.1B). Summit Therapeutics PLC has negative trailing earnings, so its P/E is not meaningful; Halozyme Therapeutics, Inc. trades at 32.4×. Halozyme Therapeutics, Inc. grew revenue faster over the last twelve months: 41.2% against −61.0%. Halozyme Therapeutics, Inc. has the higher net margin (24.9% vs 0.00%) and the higher return on invested capital (18.1% vs 0.00%). Across the 19 metrics below, Halozyme Therapeutics, Inc. leads on 14 and Summit Therapeutics PLC on 5.

Valuation

Metric HALO SMMT Biotechnology median
P/E 32.36 n/m 7.88
P/S 8.03 17,230.45 11.47
P/B 93.06 19.28 2.52
Price to free cash flow 16.57 n/m 21.16
EV/EBITDA 21.24 n/m 0.74
EV/Sales 9.18 16,392.16 10.73
Earnings yield 3.09% (7.17%) (28.84%)
Free cash flow yield 6.04% (3.79%) (23.03%)

Profitability

Metric HALO SMMT Biotechnology median
Gross margin 82.42% 100.00% 65.16%
Operating margin 35.90% 0.00% 0.00%
Net margin 24.86% 0.00% 0.00%
Free cash flow margin 48.46% 0.00% 0.00%
Return on equity 173.67% (192.50%) (57.72%)
Return on assets 17.86% (159.09%) (49.22%)
Return on invested capital 18.13% 0.00% 0.00%

Growth

Metric HALO SMMT Biotechnology median
Revenue growth (TTM) 41.15% (61.03%) 5.64%
EPS growth (last fiscal year) (25.36%) (364.52%) —
Revenue growth, 5-year CAGR 39.16% (46.49%) 8.40%
Net income growth, 5-year CAGR 19.68% 0.00% 0.00%

Health

Metric HALO SMMT Biotechnology median
Debt to equity 14.95 0.00 0.00
Current ratio 2.71 6.96 4.73
Net debt to EBITDA 3.56 0.65 0.96

Dividend

Metric HALO SMMT Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric HALO SMMT Biotechnology median
Market cap 13.08b 13.12b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack